These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1426 related items for PubMed ID: 10430613

  • 1. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T, Hill GR, Pan L, Brinson YS, van den Brink MR, Cooke KR, Ferrara JL.
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [Abstract] [Full Text] [Related]

  • 2. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation.
    Reddy P, Teshima T, Hildebrandt G, Duffner U, Maeda Y, Cooke KR, Ferrara JL.
    Blood; 2002 Nov 01; 100(9):3429-31. PubMed ID: 12384449
    [Abstract] [Full Text] [Related]

  • 3. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
    Tsukada N, Kobata T, Aizawa Y, Yagita H, Okumura K.
    Blood; 1999 Apr 15; 93(8):2738-47. PubMed ID: 10194454
    [Abstract] [Full Text] [Related]

  • 4. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
    Pan L, Teshima T, Hill GR, Bungard D, Brinson YS, Reddy VS, Cooke KR, Ferrara JL.
    Blood; 1999 Jun 15; 93(12):4071-8. PubMed ID: 10361103
    [Abstract] [Full Text] [Related]

  • 5. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD, Becker EE, Truitt RL.
    Biol Blood Marrow Transplant; 1999 Jun 15; 5(3):123-32. PubMed ID: 10392958
    [Abstract] [Full Text] [Related]

  • 6. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
    Sykes M, Abraham VS, Harty MW, Pearson DA.
    J Immunol; 1993 Jan 01; 150(1):197-205. PubMed ID: 8093257
    [Abstract] [Full Text] [Related]

  • 7. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
    Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, Ferrara JL, Burakoff SJ, van den Brink MR.
    Blood; 2001 May 01; 97(9):2886-95. PubMed ID: 11313285
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH, Breglio J, Nagel G, Eckhaus MA, Gress RE.
    J Immunol; 1996 Dec 01; 157(11):4811-21. PubMed ID: 8943383
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
    Yang YG, Sergio JJ, Pearson DA, Szot GL, Shimizu A, Sykes M.
    Blood; 1997 Dec 01; 90(11):4651-60. PubMed ID: 9373279
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
    Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, Crawford JM, Ferrara JL.
    J Clin Invest; 1999 Aug 01; 104(4):459-67. PubMed ID: 10449438
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS.
    Nat Med; 2003 Sep 01; 9(9):1144-50. PubMed ID: 12925844
    [Abstract] [Full Text] [Related]

  • 15. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.
    Blazar BR, Lees CJ, Martin PJ, Noelle RJ, Kwon B, Murphy W, Taylor PA.
    J Immunol; 2000 Nov 01; 165(9):4901-9. PubMed ID: 11046015
    [Abstract] [Full Text] [Related]

  • 16. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects.
    Sykes M, Harty MW, Szot GL, Pearson DA.
    Blood; 1994 May 01; 83(9):2560-9. PubMed ID: 7909457
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 72.